JPWO2020030593A5 - - Google Patents

Claims (14)

A composition for treating, preventing, delaying, or reducing the risk or severity of graft-versus-host disease in a subject, the substance selected from adsorbents and antibiotic-inactivating enzymes. Composition containing . The composition according to claim 1, wherein the subject to be treated receives, plans to, or has already received a disbiosis-inducing drug. The composition according to claim 2, wherein the disbiosis-inducing drug is an antibiotic administered for the treatment or prevention of infection. The composition according to any one of claims 1 to 3, wherein the substance is an adsorbent. The composition according to claim 4, wherein the adsorbent is activated carbon. The adsorbent
--The core containing the adsorbent and
The composition according to claim 4 or 5, which is present in the formulation comprising a layer of an external coating formed around the core such that the adsorbent is released from the formulation in the lower part of the intestine. The composition according to claim 6, wherein the core further comprises carrageenan such as kappa-carrageenan. The substance is an antibiotic-inactivating enzyme, and the subject has, is, or has already received, an antibiotic for the prevention or treatment of infection, and the enzyme. The composition according to any one of claims 1 to 3, which is suitable for inactivating the antibiotic. (i) the enzyme is a beta-lactamase, in particular VIM-2 or rivaxamase, and the antibiotic is a beta-lactam antibiotic, or (ii) the enzyme is an erythromycin esterase, the antibiotic. The composition according to claim 8, wherein the substance is a macrolide. The enzyme is a hybrid protein molecule comprising two antibiotic-inactivating enzymes bound together, wherein the two enzymes are the same antibiotic or different antibiotics, or antibiotics of the same or different types. The composition according to claim 8, which is inactivated. The composition according to any one of claims 8 to 10, which is formulated in a composition for oral administration suitable for the release of the antibiotic-inactivating enzyme in a desired portion of the intestine such as the lower part of the intestine . The composition according to any one of claims 2 to 11, wherein the disbiosis-inducing drug is an antibiotic selected in the group consisting of the following:
--Beta-lactams including:
--Penicillin system (eg, penicillin G, penicillin V, ampicillin, amoxicillin, bacampicillin, carbenicillin, carbenicillin indanyl, ticarcillin, azlocillin, mezlocillin, piperacillin, etc.),
--Penicillinase resistant penicillins (eg, methicillin, oxacillin, cloxacillin, dicloxacillin, nafcillin, etc.),
--Cephalosporins, such as first-generation cephalosporins (eg, cephalosporins, cephalexins, cefurazines, cephalosporins, cephapillins, cephazolines, etc.), second-generation cephalosporins (eg, cefachlor, cephamandol, cephonicid, cephoxitin, etc.) , Cefotetan, cefuroxime, cefuroxime axetyl, cefinetazole, cefprodil, loracalvev, cephoranide, etc.), third generation cephalosporins (eg, cefepim, cefoperazone, cefotaxime, ceftizoxime, ceftriaxone, ceftriaxone, ceftriaxone, ceftriaxim (Ceftibutene, etc.), 4th generation cephalosporins (eg, cefcridin, cefepim, cefotaxime, cefpirom, ceftriaxone, etc.), 5th generation and further generations of cephalosporins (eg, ceftviprol, cephthalolin, ceftrozan, etc.) ,
--Carbapenem (eg, imipenem, meropenem, ertapenem, doripenem, etc.),
--Monobactam (for example, Aztreonam, etc.)
—— Quinolones (eg, nalidixic acid) and fluoroquinolones (eg, synoxacin, ciprofloxacin, moxifloxacin, levofloxacin, ofloxacin, gatifloxacin, gerifloxacin, norfloxacin, etc.),
--Sulfonamides (eg, sulfanilamide, sulfadiazine, sulfamethoxazole, sulfisoxazole, sulfacetamide, sulfamethoxydiadine, etc.),
--Aminoglycosides (eg, streptomycin, gentamicin, tobramycin, amikacin, netylmycin, kanamycin, neomycin B, neomycin C and neomycin E, spectinomycin, puromycin, gentamicin, etc.),
--Tetracycline (for example, tetracycline, chlortetracycline, oxytetracycline, metacycline, doxycycline, minocycline, chigecycline, ellabacycline, etc.),
--Macrolides (eg, erythromycin, azithromycin, clarithromycin, fidaxomicin, telithromycin, josamycin, oleandomycin, spiramycin, tyrosin, roxithromycin, cethromycin, sorisromycin, etc.),
--Glycopeptides (eg vancomycin, oritabancin, teravancin, teicoplanin, dalvabancin, ramopranin, etc.),
--Oxazolidinone-based (eg, linezolid, positive zolide, tedizolid, radezolide, cycloserine, etc.),
--Phenicol system (for example, chloramphenicol, cheamphenicol, etc.),
--Lincomycin type (for example, clindamycin, lincomycin, etc.),
--Streptogramin-based (eg, pristinamycin, quinupristin / dalhopristin, Virginiamycin, etc.),
--Polymyxin system (eg, polymyxin A, polymyxin B, polymyxin C, polymyxin D, polymyxin E1 (cholistin A), or polymyxin E2, colistin B or colistin C, etc.),
--Diaminopyrimidines (eg, trimethoprim (often used in combination with sulfamethoxazole), pyrazinamide, etc.),
--Sulfone system (eg, dapsone, sodium sulfoxone, etc.),
--Para-Aminobenzoic acid,
--Bacitracin,
--Isoniazid,
--Rifampicin (eg, rifampicin, rifabutin, rifapentine, rifalacil, limamixin, etc.),
--Etambutol,
--Ethionamide,
--Capreomycin, and
--Clofazimine. The composition according to any one of claims 1 to 12, wherein the subject is a recipient or may be a recipient of allogeneic cells, tissues, or organs. The composition according to any one of claims 1 to 13, wherein the subject is a recipient or may be a recipient of hematopoietic stem cells.